Related Experiment Videos
Functional Genomics meets neurodegenerative disorders. Part II: application and data integration
Frederic Hoerndli1, Della C David, Jürgen Götz
1Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland.
Progress in Neurobiology
|September 20, 2005
Summary
Transcriptomic and proteomic technologies are revolutionizing neurodegenerative disorder research. Analyzing large datasets from human and animal samples will redefine diseases based on biochemistry, improving future treatments.
Area of Science:
- Neuroscience
- Genomics
- Proteomics
Background:
- Transcriptomic and proteomic techniques are increasingly applied to neurodegenerative disorders.
- Studies encompass Huntington's disease, prion diseases, ALS, Alzheimer's, FTD, and Parkinson's disease.
- Data is sourced from human tissues, cerebrospinal fluid, cell cultures, and animal models.
Purpose of the Study:
- To review the application of transcriptomic and proteomic technologies in neurodegenerative disorders.
- To address challenges in data analysis and interpretation from large-scale omics datasets.
- To explore the future impact of these technologies on disease classification and treatment.
Main Methods:
- Application of transcriptomic and proteomic techniques.
- Analysis of diverse sample types including human and animal biological specimens.
- Focus on data normalization and validation for reliability.
Main Results:
- Large datasets generated from various neurodegenerative disease models.
- Identification of challenges in extracting meaningful and consistent information.
- Highlighting the critical role of data normalization and validation.
Conclusions:
- Omics data analysis presents significant challenges but offers profound insights.
- Biochemical criteria derived from transcriptomic and proteomic data will redefine disease entities.
- This reclassification will significantly impact therapeutic strategies for neurodegenerative disorders.